XBI vs LABU ETF Comparison: AI Score, Valuation, Performance and Upside
XBI and LABU both track the S&P Biotechnology Select Industry Index, but for completely different investor types. XBI is a standard equity ETF suitable for long-term investors wanting diversified biotech exposure. LABU is a 3x daily leveraged ETF designed exclusively for short-term traders exploiting biotech momentum — its daily rebalancing creates volatility decay that makes it unsuitable for long-term holding. These are not equivalent alternatives.
XBI vs LABU is the standard equal-weight biotech ETF for long-term investors seeking diversified small-cap biotech exposure (XBI) versus the 3x daily leveraged biotech tactical trading vehicle for short-duration momentum plays on the same index (LABU) — core biotech holding vs short-term leveraged speculation tool.
XBI holds the edge across 4 of 5 key metrics in this comparison. LABU has delivered stronger 1-year price return (+75.17% vs +35.48% for XBI).
- prefer long-term biotech sector exposure across 100+ companies with equal-weight methodology emphasizing small and mid-cap biotech growth potential
- value XBI as a core biotech portfolio allocation for investors with 3–5+ year time horizons weathering FDA binary event volatility
- want the most liquid and widely used biotech ETF for options hedging, sector rotation, and biotech benchmark comparison
- are comfortable with high biotech sector volatility, binary FDA approval risk, and small-cap biotech funding environment sensitivity
- need short-term tactical 3x leveraged exposure to biotech momentum — holding LABU for days or weeks around major FDA catalysts or biotech sector rallies
- understand daily rebalancing volatility decay and actively manage holding periods to avoid long-term beta decay destruction
- want leveraged biotech exposure without margin accounts or options complexity for tactical momentum trading
- are comfortable with catastrophic downside risk (33% XBI decline = near-total LABU loss) and never intend to hold LABU as a core portfolio position
| Metric | XBI | LABU |
|---|---|---|
| ETF scorei | 27.5 | 22.0 |
| Latest closei | $152.05 | $228.38 |
| 1M returni | -1.54% | -8.18% |
| 3M returni | +3.22% | +0.15% |
| 6M returni | +14.01% | +22.73% |
| 1Y returni | +35.48% | +75.17% |
The ETF score weights long-term returns and risk-adjusted performance most heavily, but still rewards low expense ratios, larger fund size, and broader diversification — so it can favor low-cost, broad, mega-cap funds over smaller thematic or actively-managed funds even when the latter have delivered stronger returns.
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | XBI | LABU |
|---|---|---|
| 1Y ago | $13.96K (+39.6%) started 2025-11-03 | $19.08K (+90.8%) started 2025-11-03 |
| 5Y ago | $11.48K (+14.8%) started 2021-11-03 | $1.8K (-82.0%) started 2021-11-03 |
| 10Y ago | $29.33K (+193.3%) started 2016-11-03 | $4.91K (-50.9%) started 2016-11-03 |
Hypothetical — past performance does not guarantee future results.
| Metric | XBI | LABU |
|---|---|---|
| Expense ratioi | 0.35% | 0.96% |
| Total assets (AUM)i | $10.36B | $616.19M |
| Dividend yieldi | 0.35% | 0.34% |
| Trailing P/Ei | N/A | N/A |
| Betai | 0.88 | 2.58 |
| 52-week change | 35.48% | 75.17% |
| Metric | XBI | LABU |
|---|---|---|
| 1Y returni | +35.48% | +75.17% |
| 6M returni | +14.01% | +22.73% |
| 3M returni | +3.22% | +0.15% |
| 1M returni | -1.54% | -8.18% |
| 1Y Sharpe ratio | 1.13 | 1.12 |
| Betai | 0.88 | 2.58 |
| Dividend yieldi | 0.35% | 0.34% |
| 5Y CAGR | +2.67% | -29.34% |
Over the past year, XBI and LABU have moved strongly in the same direction (correlation of 1.00), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | XBI | LABU |
|---|---|---|---|
| 1Y | Growthi | +39.00% | +89.83% |
| CAGRi | +39.15% | +90.25% | |
| Volatilityi | 29.11% | 86.68% | |
| Sharpe ratioi | 1.13 | 1.12 | |
| Sortino ratioi | 1.73 | 1.72 | |
| Max drawdowni | 14.88% | 41.78% | |
| Current drawdowni | 10.32% | 33.13% | |
| Avg drawdowni | 4.21% | 13.65% | |
| Ulcer Indexi | 5.41% | 16.98% | |
| Max daily dropi | 4.39% | 12.94% | |
| Max wkly dropi | 7.48% | 21.42% | |
| 5Y | Growthi | +14.06% | -82.36% |
| CAGRi | +2.67% | -29.34% | |
| Volatilityi | 32.51% | 96.61% | |
| Sharpe ratioi | 0.11 | 0.08 | |
| Sortino ratioi | 0.15 | 0.11 | |
| Max drawdowni | 53.18% | 97.12% | |
| Current drawdowni | 10.32% | 82.36% | |
| Avg drawdowni | 28.87% | 86.87% | |
| Ulcer Indexi | 31.88% | 87.70% | |
| Max daily dropi | 8.21% | 24.52% | |
| Max wkly dropi | 20.07% | 52.77% | |
| 10Y | Growthi | +189.21% | -52.20% |
| CAGRi | +11.21% | -7.12% | |
| Volatilityi | 31.95% | 95.30% | |
| Sharpe ratioi | 0.35 | 0.35 | |
| Sortino ratioi | 0.51 | 0.51 | |
| Max drawdowni | 63.89% | 98.96% | |
| Current drawdowni | 12.03% | 93.65% | |
| Avg drawdowni | 27.19% | 67.27% | |
| Ulcer Indexi | 33.80% | 74.87% | |
| Max daily dropi | 12.35% | 33.37% | |
| Max wkly dropi | 23.56% | 59.34% |
| Category | XBI | LABU |
|---|---|---|
| Fund name | State Street SPDR S&P Biotech ETF | Direxion Daily S&P Biotech Bull 3X Shares |
| Type | ETF | ETF |
| Expense ratioi | 0.35% | 0.96% |
| Total assets (AUM)i | $10.36B | $616.19M |
| Dividend yieldi | 0.35% | 0.34% |
- Equal-weight methodology prevents large-cap dominance — XBI gives Regeneron and a small preclinical biotech similar weighting, maintaining exposure to high-upside early-stage biotechs
- Broad 100+ company diversification reduces single-stock binary event risk compared to holding individual biotechs
- High liquidity and options market depth make XBI the standard biotech hedging and speculation vehicle
- 3x daily leverage amplifies gains during biotech bull runs — LABU can generate extraordinary returns in short-duration biotech rallies
- Provides leveraged biotech exposure without margin accounts or options — accessible to retail investors wanting biotech tactical exposure
- Same index as XBI enables straightforward tracking of sector momentum with leveraged amplification
- Equal-weight small/mid-cap biotech exposure creates higher drawdown risk than market-cap weighted biotech ETFs during biotech bear markets
- Biotech is driven by binary FDA decisions — even diversified biotech ETFs can fall sharply when multiple high-profile drugs fail trials simultaneously
- Biotech funding environments (interest rates, IPO market) heavily affect small biotech valuations and XBI price
- Volatility decay (beta decay) causes LABU to lose value over time in volatile markets even if the index is flat — LABU is demonstrably not suitable for long-term holding
- 3x leverage amplifies losses equally: a 33% XBI decline wipes out LABU entirely — extreme downside risk during biotech drawdowns
- LABU requires active monitoring and short holding periods — most retail investors who hold LABU too long experience significant underperformance vs 3x the XBI return due to daily rebalancing drag
Compare more than two at a time
This page is a fixed writeup on XBI and LABU. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside XBI and LABU, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.